2015-04-17 07:50 ET - News Release
Mr. Dan Legault reports
ANTIBE THERAPEUTICS ANNOUNCES ADDITIONAL VALIDATION DATA ON ATB-346
Antibe Therapeutics Inc. released today the results of additional testing of the in vivo
activity of its lead anti-inflammatory drug, ATB-346.
The results support the company's earlier communication that
be effective at much lower doses than previously expected and that
once-daily dosing may be effective. Together, over 600 blood samples
phase 1 human clinical trial were independently analyzed to assess
ability of ATB-346, at doses ranging from 25 milligrams to 1,000
milligrams, to inhibit the
enzyme cyclooxygenase (COX). The reduction of pain and
non-steroidal anti-inflammatory drugs is attributed to their
ability to inhibit COX activity.
Substantial inhibition of COX was observed at doses of ATB-346 as low as
75 milligrams, and the inhibition was maintained for 24 hours. The company continues to conduct validation studies and will report to
the market as they proceed.